'On consolidated basis
Quarter ended December 2024 compared with Quarter ended December 2023.
Net sales (including other operating income) of Natco Pharma has declined 37.41% to Rs 474.8 crore.
Profit before interest, tax and other unallocable items (PBIT) has slumped 35.57% to Rs 168.10 crore.
Overall PBIT margin rose from 34.39% to 35.40%.
Operating profit margin has declined from 35.34% to 8.17%, leading to 85.53% decline in operating profit to Rs 38.80 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 12.71% to 14.43%. Purchase of finished goods cost rose from 5.06% to 7.76%. Employee cost increased from 16.81% to 28.11%. Other expenses rose from 28.46% to 42.00%.
Other income rose 376.49% to Rs 176.3 crore. PBIDT fell 29.50% to Rs 215.1 crore. Provision for interest fell 4.35% to Rs ...
Pleaselogin & subscribe to view the full report.
More Reports
-
-
Revenue up by 3.3% YoY to Rs 4304.7 crore in Q3FY2025
-
-
|
|